Impact of PARP inhibitors on progression-free survival in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective analysis

Abstract Objective Poly (ADP-ribose) polymerase (PARP) inhibitors such as olaparib and niraparib have shown promise in extending progression-free survival (PFS) in patients with platinum-sensitive recurrent (PSR) epithelial ovarian cancer. In this retrospective study, we aimed to present our own dat...

Full description

Bibliographic Details
Published in:	World Journal of Surgical Oncology
Main Authors:	Yumei Zhou, Junfen Xu
Format:	Article
Language:	English
Published:	BMC 2024-10-01
Subjects:	PSR epithelial ovarian cancer PARP inhibitors Maintenance therapy PFS
Online Access:	https://doi.org/10.1186/s12957-024-03562-8

Similar Items

Efficacy of a platinum-based chemotherapy rechallenge for platinum-sensitive recurrence after PARP inhibitor maintenance
by: Takehiro Nakao, et al.
Published: (2024-10-01)

Efficacy and safety of PARP inhibitors for maintenance treatment of ovarian cancer, regardless of BRCA or HRD status: a comprehensive updated meta-analysis
by: Yanhui Li
Published: (2023-12-01)

Interstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: A case report
by: Yuan Bian, et al.
Published: (2022-12-01)

Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives – a review
by: Sudeep Gupta, et al.
Published: (2019-11-01)

High Expression of PARP1 in Tumor and Stroma Cells Predicts Different Prognosis and Platinum Resistance in Patients With Advanced Epithelial Ovarian Cancer
by: Wei-Wei Zuo, et al.
Published: (2022-07-01)

Corrigendum: High expression of PARP1 in tumor and stroma cells predicts prognosis and platinum resistance in patients with advanced epithelial ovarian cancer
by: Wei-Wei Zuo, et al.
Published: (2023-06-01)

A real-world study of treatment patterns following disease progression in epithelial ovarian cancer patients undergoing poly-ADP-ribose polymerase inhibitor maintenance therapy
by: Nan Zhang, et al.
Published: (2024-03-01)

PARP Inhibitors in the Treatment of Ovarian Cancer
by: Andrzej Paweł Zuzak, et al.
Published: (2025-02-01)

PARP INHIBITORS IN OVARIAN CANCER: TOXICITY PROFILE
by: S. V. KHOKHLOVA, et al.
Published: (2017-06-01)

The evolving role of PARP inhibitors in advanced ovarian cancer
by: Levva Sofia, et al.
Published: (2021-08-01)

A real-world study of PARP inhibitors in 75 patients with platinum-sensitive recurrent ovarian cancer from China
by: Jinghong Chen, et al.
Published: (2024-01-01)

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
by: Colombo I, et al.
Published: (2018-03-01)

Maintenance therapy for newly diagnosed epithelial ovarian cancer– a review
by: Shona Nag, et al.
Published: (2022-07-01)

Use of First-Line PARP Inhibitors in Ovarian Cancer
by: Ursula Hasler-Strub
Published: (2020-11-01)

A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers
by: Anna V. Tinker, et al.
Published: (2022-06-01)

Olaparib as maintenance therapy and salvage therapy in recurrent ovarian cancer: The early experience in Taiwan
by: Chia-Chen Hsu, et al.
Published: (2021-07-01)

Application of PARP inhibitors combined with immune checkpoint inhibitors in ovarian cancer
by: Fen Xiao, et al.
Published: (2024-08-01)

Survival analysis of recurrent ovarian cancer under different PARP inhibitor treatment patterns: a single-center retrospective study
by: Jingtian Shen, et al.
Published: (2025-01-01)

HELQ upregulates PARP1 to drive platinum resistance and predict therapeutic response in ovarian cancer
by: Shuran Tan, et al.
Published: (2025-07-01)

Repression of PFKFB3 sensitizes ovarian cancer to PARP inhibitors by impairing homologous recombination repair
by: Yinan Xiao, et al.
Published: (2025-01-01)

The use of PARP inhibitors as maintenance therapy in ovarian carcinosarcoma: A case series
by: Andreea I Dinicu, et al.
Published: (2025-10-01)

Prior authorization for FDA-approved PARP inhibitors in ovarian cancer
by: Anna Jo Bodurtha Smith, et al.
Published: (2024-04-01)

PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in ovarian cancer
by: Chaohua Liu, et al.
Published: (2024-05-01)

Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain – A GEICO study
by: Alfonso Yubero, et al.
Published: (2022-11-01)

Global research trends in PARP inhibitors for ovarian cancer: a bibliometric analysis
by: Xiaodong Wang, et al.
Published: (2025-08-01)

PARP Inhibitors in Ovarian Cancer: Resistance Mechanisms, Clinical Evidence, and Evolving Strategies
by: Shant Apelian, et al.
Published: (2025-05-01)

Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer
by: Jiang X, et al.
Published: (2019-05-01)

Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer
by: Sanat Kulkarni, et al.
Published: (2024-07-01)

Consensus on the management of platinum-sensitive high-grade serous epithelial ovarian cancer in Lebanon
by: Reem Abdallah, et al.
Published: (2023-06-01)

Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors
by: Michalis Liontos, et al.
Published: (2021-10-01)

A case report of long-term successful use of maintenance therapy with PARP inhibitors in the primary treatment of advanced BRCA-associated ovarian cancer
by: О. N. Churuksaeva, et al.
Published: (2023-09-01)

Difluoromethylornithine (DFMO) Enhances the Cytotoxicity of PARP Inhibition in Ovarian Cancer Cells
by: Olivia El Naggar, et al.
Published: (2022-05-01)

Imaging-based assessment of response to olaparib in platinum-sensitive relapsed ovarian cancer patients
by: Maria Delgado-Ortet, et al.
Published: (2025-06-01)

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting
by: Karolina N. Dziadkowiec, et al.
Published: (2017-02-01)

KIAA1529 regulates RAD51 expression to confer PARP inhibitors resistance in ovarian cancer
by: Yuan Qiao, et al.
Published: (2022-10-01)

Bevacizumab in Platinum-Sensitive Recurrent Epithelial Ovarian Cancer: A Risk-Stratified Analysis
by: İrem Öner, et al.
Published: (2025-06-01)

Tailored Treatment Strategies in First Line Therapy for Ovarian Cancer Patients: A Critical Review of the Literature
by: Daniela Luvero, et al.
Published: (2024-06-01)

KAT6A Condensates Impair PARP1 Trapping of PARP Inhibitors in Ovarian Cancer
by: Zhiyan Zhan, et al.
Published: (2024-09-01)

Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer
by: Shane O’Brien, et al.
Published: (2023-08-01)

Exploring the radiochemistry of PARP inhibitors: a new era in therapy and imaging
by: Gianluca Destro, et al.
Published: (2025-07-01)